Ann: Imugene completes $35M Placement & Launches c.$30M SPP, page-247

Strategy has obviously changed from last time PH outlined it, i.e. sell off the assets at end of Phase 2. He admits there has been a strategy change so why not clearly outline it then? I'm sure the specialist life science investors have been well briefed so time to spell it out to mums and dads. People can slam me here if they like saying it's obvious reas between the lines. However when you read the threads it's all speculation. And we as shareholders deserve more, we shouldn't need to read between the lines, I'm simple minded and I want my Board to present a clear strategy to me. That's my view. Sure they may be building an empire here but we await results and are still at the mercy of the FDA.